Co-crystals
AssigneeCereSpir Incorporated
InventorsDaniel G. Chain, Ronald Mueller
Life of this patent
Estimating the term…
Abstract
Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.
Claims10
A method of treating Alzheimer's disease in a human in need thereof, comprising administering a therapeutically effective dosage regimen of a co-crystal comprising itanapraced and nicotinamide to the human,
- wherein the co-crystal has an X-ray Powder Diffraction Pattern (XRPD) with specific peaks, expressed in 2θ produced from a Cu radiation source (λ=1.54 Å after Ni filtering), at about 14.63°;
- 14.90°;
- 15.56°;
- 16.71°;
- 18.24°;
- 18.46°, 20.03°;
- 20.27°;
- 22.01°, 22.27°;
- 24.17°;
- 24.47°;
- 26.14°;
- 26.47°;
- 27.83°;
- 28.85°;
- 29.97°;
- 30.64°;
- 32.42°;
- 34.07°;
- and 39.14°, all +/−0.2 degrees 2θ.
Dependencies are inferred from the claim text.